Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 9, 2013 - Issue 11
Submit an article Journal homepage
223
Views
24
CrossRef citations to date
0
Altmetric
Reviews

Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives

Jens SchmidtClinic for Neurology, University Medical Centre, Waldweg 33, 37073 Göttingen, Germany;Department of Neuroimmunology, Institute for Multiple Sclerosis Research and Hertie Foundation, University Medical Center, Waldweg 33, 37073 Göttingen, GermanyCorrespondence[email protected] (alternative contact details for MC Dalakas)
&
Marinos C DalakasDepartment of Pathophysiology, Neuroimmunology Unit, University of Athens Medical School, 75 Mikras Asias Str. 115 27Athens, Greece
Pages 1125-1133 | Published online: 10 Jan 2014

References

  • Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J. Clin. Neurosci. 15(12), 1350–1353 (2008).
  • Benveniste O, Guiguet M, Freebody J et al. Long-term observational study of sporadic inclusion body myositis. Brain 134(Pt 11), 3176–3184 (2011).
  • Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 134(Pt 11), 3167–3175 (2011).
  • Rose M. 188th ENMC International Workshop: Inclusion Body Myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscul. Disord. ( 2013) (Submitted).
  • Badrising UA, Maat-Schieman M, van Duinen SG et al. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology 55(9), 1385–1387 (2000).
  • Griggs RC, Askanas V, DiMauro S et al. Inclusion body myositis and myopathies. Ann. Neurol. 38(5), 705–713 (1995).
  • Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J. Neurol. Neurosurg. Psychiatry ( doi:10.1136/jnnp-2013–305690) (2013) ( Epub ahead of print).
  • Benveniste O, Hilton-Jones D. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul.Disord. (2010).
  • Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul. Disord. 20(2), 142–147 (2010).
  • Chahin N , Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70(6), 418–424 (2008).
  • Koffman BM, Rugiero M, Dalakas MC. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis. Muscle Nerve 21(1), 115–117 (1998).
  • Mastaglia FL, Needham M, Scott A et al. Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul. Disord. 19(11), 763–765 (2009).
  • Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J. Neuropathol. Exp. Neurol. 63(5), 484–498 (2004).
  • Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget’s disease of the bone and fronto-temporal dementia. Neuromuscul. Disord. 19(5), 308–315 (2009).
  • Dimitri D, Benveniste O, Dubourg O et al. Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain 129(Pt 4), 986–995 (2006).
  • Salajegheh M, Rakocevic G, Raju R, Shatunov A, Goldfarb LG, Dalakas MC. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 69(17), 1672–1679 (2007).
  • Fyhr IM, Moslemi AR, Mosavi AA, Lindberg C, Tarkowski A, Oldfors A. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J. Neuroimmunol. 79(2), 185–189 (1997).
  • Goebels N, Michaelis D, Wekerle H, Hohlfeld R. Human myoblasts as antigen-presenting cells. J. Immunol. 149(2), 661–667 (1992).
  • Wiendl H, Mitsdoerffer M, Schneider D et al. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126(Pt 5), 1026–1035 (2003).
  • Murata K , Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am. J. Pathol. 155(2), 453–460 (1999).
  • Schmidt J, Rakocevic G, Raju R, Dalakas MC. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8(+) T cell cytotoxicity. Brain 127, 1182–1190 (2004).
  • Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 26(7), 373–380 (2005).
  • Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 131(Pt 5), 1228–1240 (2008).
  • De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul. Disord. 9(4), 239–246 (1999).
  • De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM. Differential expression of chemokines in inflammatory myopathies. Neurology 58(12), 1779–1785 (2002).
  • Schmidt J. Of amyloid and inflammation: causes of chronic muscle disease. e-Neuroforum 2010(4), 81–88 (2010).
  • Dalakas MC, Illa I, Gallardo E, Juarez C. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann. Neurol. 41(1), 100–104 (1997).
  • Bradshaw EM, Orihuela A, McArdel SL et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J. Immunol. 178(1), 547–556 (2007).
  • Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PLoS ONE 6(5), e20266- (2011).
  • Pluk H, van Hoeve BJ, van Dooren SH et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in inclusion body myositis. Ann. Neurol. 73(3), 397–407 (2013).
  • Larman HB, Salajegheh M, Nazareno R et al. Cytosolic 5’-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann. Neurol. 73(3), 408–418 (2013).
  • Askanas V, Engel WK, Nogalska A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J. Neuropathol. Exp. Neurol. 71(8), 680–693 (2012).
  • Sarkozi E, Askanas V, Johnson SA, Engel WK, Alvarez RB. Beta-amyloid precursor protein messenger-RNA is increased in inclusion-body myositis muscle. Neuroreport 4(6), 815–818 (1993).
  • Vattemi G, Engel WK, McFerrin J, Buxbaum JD, Pastorino L, Askanas V. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 358(9297), 1962–1964 (2001).
  • Vattemi G, Nogalska A, King EW, D’Agostino C, Checler F, Askanas V. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol. 117(5), 569–574 (2009).
  • Askanas V, McFerrin J, Parkmatsumoto YC, Lee CS, Engel WK. Glucocorticoid increases acetylcholinesterase and organization of the postsynaptic membrane in innervated cultured human muscle. Exp. Neurol. 115(3), 368–375 (1992).
  • Nogalska A, D’Agostino C, Engel WK, Klein WL, Askanas V. Novel demonstration of amyloid-beta oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol. 120(5), 661–666. (2010).
  • Abdo WF, van Mierlo T, Hengstman GJ, Schelhaas HJ, van Engelen BG, Verbeek MM. Increased plasma amyloid-beta42 protein in sporadic inclusion body myositis. Acta Neuropathol. 118(3), 429–431 (2009).
  • Terracciano C, Nogalska A, Engel WK, Askanas V. In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis. J. Neurochem. 112(2), 389–396 (2010).
  • Fratta P, Engel WK, McFerrin J, Davies KJ, Lin SW, Askanas V. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am. J. Pathol. 167(2), 517–526 (2005).
  • Lunemann JD, Schmidt J, Schmid D et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann.Neurol. 61(5), 476–483 (2007).
  • Nogalska A, D’Agostino C, Terracciano C, Engel WK, Askanas V. Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am. J. Pathol. 177(3), 1377–1387 (2010).
  • D’Agostino C, Nogalska A, Cacciottolo M, Engel WK, Askanas V. Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol. 122(5), 627–636 (2011).
  • Cacciottolo M, Nogalska A, D’Agostino C, Engel WK, Askanas V. Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres. Neuropathol. Appl. Neurobiol. doi: 10.1111/nan.12038 (2013) (Epub ahead of print).
  • Keller CW, Fokken C, Turville SG et al. TNF-{alpha} Induces Macroautophagy and Regulates MHC Class II Expression in Human Skeletal Muscle Cells. J. Biol. Chem. 286(5), 3970–3980 (2011).
  • Keller CW, Schmitz M, Munz C, Lunemann JD, Schmidt J. TNF-alpha upregulates macroautophagic processing of APP/beta-amyloid in a human rhabdomyosarcoma cell line. J. Neurol. Sci. 325(1–2), 103–107 (2013).
  • Morosetti R, Mirabella M, Gliubizzi C et al. MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. Proc. Natl Acad. Sci.USA 103(45), 16995–17000 (2006).
  • Morosetti R, Broccolini A, Sancricca C et al. Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol.Aging 31(7), 1205–1214 (2010).
  • Morosetti R, Gliubizzi C, Sancricca C et al. TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis. Am. J. Pathol. 180(4), 1603–1613 (2012).
  • Banwell BL , Engel AG. alpha B-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 54(5), 1033–1041 (2000).
  • Muth IE, Barthel K, Bahr M, Dalakas MC, Schmidt J. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J. Neurol. Neurosurg. Psychiatry 80(12), 1344–1349 (2009).
  • Schmidt J, Barthel K, Zschuntzsch J et al. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1beta-induced accumulation of beta-amyloid and cell death. Brain 135(Pt 4), 1102–1114 (2012).
  • Vattemi G, Engel WK, McFerrin J, Askanas V. Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am. J. Pathol. 164(1), 1–7 (2004).
  • Colombo E, Romaggi S, Blasevich F et al. The neurotrophin receptor p75NTR is induced on mature myofibres in inflammatory myopathies and promotes myotube survival to inflammatory stress. Neuropathol. Appl. Neurobiol. 38(4), 367–378 (2012).
  • De Paepe B, Racz GZ, Schroder JM, De Bleecker JL. Expression and distribution of the nitric oxide synthases in idiopathic inflammatory myopathies. Acta Neuropathol.(Berl) 108(1), 37–42 (2004).
  • Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann. Neurol. 64(1), 15–24 (2008).
  • Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr. Treat. Options. Neurol 13(3), 311–323 (2011).
  • Walter MC, Lochmuller H, Toepfer M et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol. 247(1), 22–28 (2000).
  • Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56(3), 323–327 (2001).
  • Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 48(3), 712–716 (1997).
  • Zschuntzsch J, Voss J, Creus K et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and beta-amyloid in the muscle. Arthritis Rheum. 64(12), 4094–4103 (2012).
  • Dalakas MC, Rakocevic G, Schmidt J et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132(Pt 6), 1536–1544 (2009).
  • Kosmidis M, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an IL-1 receptor antagonist, in patients with inclusion body myositis (sIBM): a small pilot study. J. Neurol. Sci. doi:10.1016/j.jns.2013.08.007 (2013) ( Epub ahead of print).
  • Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol. Sci. 32(5), 841–847 (2011).
  • Cortese A, Machado P, Morrow J et al. Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul. Disord. 23(5), 404–412 (2013).
  • Lowes LP, Alfano L, Viollet L et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve 45(2), 163–168 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.